POTIGA
Total Payments
$1.1M
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1.0M | 2 | 0 |
| 2017 | $29,000 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 2 PHARMACODYNAMIC TRIAL OF EZOGABINE ON NEURONAL EXCITABILITY | GlaxoSmithKline, LLC. | $1.0M | 0 |
| sICAM5 an Inflammatory Biomarker as a Diagnostic Tool in Epilepsy | GlaxoSmithKline, LLC. | $20,000 | 0 |
| An open label study to evaluate the effects of ezogabine retigabine added to existing anti epileptic drug s on urinary voiding function in subjects with partial onset seizures | GlaxoSmithKline, LLC. | $9,000 | 0 |
Top Doctors Receiving Payments for POTIGA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Temple, TX | $1.1M | 4 |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $1.1M
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 0
- Transactions 4
About POTIGA
POTIGA is a drug associated with $1.1M in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2018. In 2018, $1.0M was paid across 2 transactions to 0 doctors.
The most common payment nature for POTIGA is "Unspecified" ($1.1M, 100.0% of total).
POTIGA is associated with 3 research studies, including "A PHASE 2 PHARMACODYNAMIC TRIAL OF EZOGABINE ON NEURONAL EXCITABILITY" ($1.0M).